| 15.21 3.28 (27.49%) | 04-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 18.12 |
1-year : | 21.16 |
| Resists | First : | 15.51 |
Second : | 18.12 |
| Pivot price | 12.32 |
|||
| Supports | First : | 12.19 |
Second : | 10.13 |
| MAs | MA(5) : | 12.84 |
MA(20) : | 11.9 |
| MA(100) : | 12.44 |
MA(250) : | 13.57  |
|
| MACD | MACD : | 0.4 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 70.5 |
D(3) : | 69.3 |
| RSI | RSI(14): 70.9 |
|||
| 52-week | High : | 20.05 | Low : | 9.81 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NVCR ] has closed above the upper band by 19.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 36.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.54 - 15.62 | 15.62 - 15.7 |
| Low: | 13.1 - 13.2 | 13.2 - 13.29 |
| Close: | 15.05 - 15.21 | 15.21 - 15.36 |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Fri, 01 May 2026
Novocure jumps after raising FY26 sales outlook, Q1 revenue beat - MSN
Fri, 01 May 2026
NovoCure Ltd (NVCR) Q1 2026 Earnings Call Highlights: Revenue Gr - GuruFocus
Fri, 01 May 2026
NovoCure (NVCR) Earnings Story Centers On 20.6% Revenue Growth Versus Ongoing Losses - simplywall.st
Thu, 30 Apr 2026
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $48 - Moomoo
Thu, 30 Apr 2026
NovoCure (NVCR) Q1 2026 Earnings Transcript - The Globe and Mail
Thu, 30 Apr 2026
NovoCure Limited (NVCR) Reports Strong Q1 2026 Results and FDA A - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 114 (M) |
| Shares Float | 95 (M) |
| Held by Insiders | 9.4 (%) |
| Held by Institutions | 86.7 (%) |
| Shares Short | 9,060 (K) |
| Shares Short P.Month | 9,130 (K) |
| EPS | -1.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.02 |
| Profit Margin | -20.8 % |
| Operating Margin | -21.4 % |
| Return on Assets (ttm) | -9.1 % |
| Return on Equity (ttm) | -38.9 % |
| Qtrly Rev. Growth | 8.1 % |
| Gross Profit (p.s.) | 4.3 |
| Sales Per Share | 5.75 |
| EBITDA (p.s.) | -1.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -49 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -12.47 |
| PEG Ratio | 0 |
| Price to Book value | 5.01 |
| Price to Sales | 2.64 |
| Price to Cash Flow | -35.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|